Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
105Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-57.39M | $-1.45 |
| 2024 | $0.00 | $-79.98M | $-2.65 |
| 2023 | $0.00 | $-98.79M | $-3.28 |
| 2022 | $0.00 | $-157.04M | $-5.30 |
| 2021 | $0.00 | $-125.75M | $-7.16 |
Social Signal Score
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $-0.14 per share
Typical surprise -22.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.11 vs $-0.20beat
- Tue, May 12$-0.22 vs $-0.18miss
- Thu, Mar 19$-0.27 vs $-0.14miss
- Thu, Nov 13$-0.30 vs $-0.04miss
- Thu, Aug 7$-0.30 vs $-0.25miss
- Mon, May 12$-0.58 vs $-0.31miss
Estimates and results for RLMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
RLMDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newszacks.com·4d ago·Neutral
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
View source ↗